TAK-279 (NDI-034858)
oral, once-daily, allosteric TYK2 inhibitor Ph. IIb for moderate-to-severe plaque psoriasis FEP+ supported VLS + core hopping w/ TYK2-JH2 Xtal structure Press release, March 18, 2023 Nimbus Therapeutics, MA / Takeda, JP
Molecules of the Month - March 2023